Online inquiry

IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14593MR)

This product GTTS-WQ14593MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14593MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6996MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ10700MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ10318MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ12492MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ15835MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ8761MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ10078MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ8175MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW